With more than 200 locations offering T1D risk screening and innovative clinical studies, it’s easy to participate in TrialNet. To find a location near you, lorem ipsum dolor sit amet. Nullam laoreet es adipiscing ut ante ipsum with TrialNet.
Led by our Clinical Center Director and Principal Investigator, Kevan Herold, MD the TrialNet team at Yale is dedicatd to preventing type 1 diabetes (T1D) and stopping progression by preserving insulin production before and after diagnosis. Details
The department has several on-going TrialNet studies, as well as ones that are open for enrollment. Stanford is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research (T1D). Details
Led by Stephen Gitelman, MD, the TrialNet team at UCSF is dedicated to preventing type 1 diabetes (T1D) and stopping disease progression by preserving insulin production before and after diagnosis. Details
Led by Peter Gottlieb, MD, the TrialNet team at the Barbara Davis Center is dedicated to preventing type 1 diabetes (T1D) and stopping disease progression by preserving insulin production before and after diagnosis. Details
Led by Principal Investigator, Lou Philipson, MD, the TrialNet team at the University of Chicago is dedicated to preventing type 1 diabetes (T1D) and stopping disease progression by preserving insulin production before and after diagnosis. Details
Led by Desmond Schatz, MD, the TrialNet team at UF is dedicated to preventing type 1 diabetes (T1D) and stopping disease progression by preserving insulin production before and after diagnosis. Details
